Cyclin L1 Polyclonal Antibody

Alternative products:Ccnl1 is an immediate-early gene with independently regulated isoforms, domain:Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions., function:Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II) . Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC) . Inhibited by the CDK-specific inhibitor p21., miscellaneous:CCNL1 is amplified in several HNSCC. May play a critical role in the formation of loco-regional metastases and an unfavorable clinical outcome of HNSCC., sequence caution:Probable cloning artifact., similarity:Belongs to the cyclin family. Cyclin L subfamily., subcellular location:More specifically found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing., subunit:Interacts with POLR2A via its hyperphosphorylated C-terminal domain (CTD) (By similarity) . Interacts with CDC2L1 or CDC2L2, and SFRS2., tissue specificity:Ubiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC) .

CCNL1; BM-001; Cyclin-L1; Cyclin-L

57018

Q9UK58

Human; Mouse; Rat

Rabbit

WB; IHC-p; IF (paraffin section) ; ELISA

Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

60

-20°C/1 year